EBCC 2024 | Molecular features of lobular breast carcinoma

Zsuzsanna Varga, MD, University Hospital Zurich, Zurich, Switzerland, gives an overview of a published paper characterizing the disease biology of lobular breast carcinoma, which is a luminal-type breast cancer. A majority of cases are HER2-, with a small number being triple negative or HER2+. In the case of HER2- lobular breast carcinoma, HER2 mutations are present, whereas no HER2 mutations are present in HER2+ lobular breast carcinoma. However, HER2 and CDK12 amplifications are present. This interview took place at the 14th European Breast Cancer Conference (EBCC) in Milan, Italy.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.